Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

被引：0
|
作者：
Seruga, B. [1 ]
Gan, H. K. [1 ]
Knox, J. J. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Div Hematol & Med Oncol, Toronto, ON, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷
关键词：
Sunitinib; sorafenib; temsirolimus; toxicity; side effects; management; RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; CARDIAC-HYPERTROPHY; INTERFERON-ALPHA; DOUBLE-BLIND; SUNITINIB; HYPOTHYROIDISM; HYPERTENSION; MANAGEMENT; SAFETY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.
引用
收藏
页码：S54 / S61
页数：8
相关论文
共 50 条
  • [11] Development of molecular targeted drugs for advanced thyroid cancer in Japan
    Takami, Hiroshi
    Ito, Koichi
    Sugino, Kiminori
    ENDOCRINE JOURNAL, 2014, 61 (09) : 833 - 839
  • [12] Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
    Lainez, Nuria
    Garcia-Donas, Jesus
    Esteban, Emilio
    Puente, Javier
    Isabel Saez, M.
    Gallardo, Enrique
    Pinto-Marin, Alvaro
    Vazquez-Estevez, Sergio
    Leon, Luis
    Garcia-Carbonero, Icar
    Suarez-Rodriguez, Cristina
    Molins, Carmen
    Climent-Duran, Miguel A.
    Lazaro-Quintela, Martin
    Gonzalez del Alba, Aranzazu
    Jose Mendez-Vidal, Maria
    Chirivella, Isabel
    Afonso, Francisco J.
    Lopez-Brea, Marta
    Sala-Gonzalez, Nuria
    Domenech, Montserrat
    Basterretxea, Laura
    Santander-Lobera, Carmen
    Gil-Arnaiz, Irene
    Fernandez, Ovidio
    Caballero-Diaz, Cristina
    Mellado, Begona
    Marrupe, David
    Garcia-Sanchez, Jose
    Sanchez-Escribano, Ricardo
    Fernandez Parra, Eva
    Villa Guzman, Jose C.
    Martinez-Ortega, Esther
    Belen Gonzalez, Maria
    Moran, Marina
    Suarez-Paniagua, Beatriz
    Lecumberri, Maria J.
    Castellano, Daniel
    BMC CANCER, 2016, 16
  • [13] Medical therapies for locally advanced/metastatic kidney cancer
    Afrit, Mehdi
    Yahyaoui, Yosra
    Bouzouita, Aderrazek
    Hantous, Saoussen
    Labidi, Soumaya
    Chebil, Mohamed
    Ben Miled, Khaoula
    Escudier, Bernard
    Boussen, Hamouda
    PRESSE MEDICALE, 2015, 44 (02): : 135 - 143
  • [14] Clinical management of metastatic kidney cancer: the role of new molecular drugs
    Vitale, Maria Giuseppa
    Carteni, Giacomo
    FUTURE ONCOLOGY, 2016, 12 (01) : 83 - 93
  • [15] Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs
    Lee, Chung-Han
    Hoetker, Andreas M.
    Voss, Martin H.
    Feldman, Darren R.
    Woo, Kaitlin M.
    Patil, Sujata
    Coskey, Devyn T.
    Akin, Oguz
    Hsieh, James J.
    Motzer, Robert J.
    CLINICAL GENITOURINARY CANCER, 2016, 14 (01) : 56 - 62
  • [16] Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center
    Vallet, Sonia
    Pahernik, Sascha
    Hoefner, Thomas
    Tosev, Georgi
    Hadaschik, Boris
    Duensing, Stefan
    Sedlaczek, Oliver
    Hohenfellner, Markus
    Jaeger, Dirk
    Gruellich, Carsten
    CLINICAL GENITOURINARY CANCER, 2015, 13 (03) : E145 - E152
  • [17] Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis
    Iacovelli, Roberto
    Sternberg, Cora N.
    Porta, Camillo
    Verzoni, Elena
    de Braud, Filippo
    Escudier, Bernard
    Procopio, Giuseppe
    CURRENT DRUG TARGETS, 2015, 16 (02) : 164 - 170
  • [18] GOAL: An inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer
    Bracarda, Sergio
    Sisani, Michele
    Marrocolo, Francesca
    Hamzaj, Alketa
    del Buono, Sabrina
    De Simone, Valeria
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 89 (03) : 386 - 393
  • [19] Risk Assessment of Drug Interaction Potential and Concomitant Dosing Pattern on Targeted Toxicities in Pediatric Cancer Patients
    Barrett, Jeffrey S.
    Patel, Dimple
    Dombrowsky, Erin
    Bajaj, Gaurav
    Skolnik, Jeffrey M.
    AAPS JOURNAL, 2013, 15 (03): : 775 - 786
  • [20] Nuances to precision dosing strategies of targeted cancer medicines
    Hopkins, Ashley M.
    Menz, Bradley D.
    Wiese, Michael D.
    Kichenadasse, Ganessan
    Gurney, Howard
    McKinnon, Ross A.
    Rowland, Andrew
    Sorich, Michael J.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (04):
12345